Zimlovisertib
Appearance
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C18H20FN3O4 |
Molar mass | 361.373 g·mol−1 |
3D model (JSmol) | |
| |
|
Zimlovisertib (PF-06650833) is a drug which acts as a selective inhibitor of the enzyme Interleukin-1 receptor-associated kinase 4 (IRAK-4). It has antiinflammatory effects and has been trialed for various indications including hidradenitis suppurativa and treatment of COVID-19 infection, and while it has not been adopted into clinical use it continues to be used for research in this area.[1][2][3]
See also
[edit]References
[edit]- ^ Zapata-Acevedo CA, Guevara-Vela JM, Popelier PL, Rocha-Rinza T (December 2022). "Binding Energy Partition of Promising IRAK-4 Inhibitor (Zimlovisertib) for the Treatment of COVID-19 Pneumonia". ChemPhysChem. 23 (24): e202200455. doi:10.1002/cphc.202200455. PMC 9538207. PMID 36044560.
- ^ Kimball AB, Peeva E, Forman S, Moiin A, Khattri S, Porter ML, et al. (March 2024). "Brepocitinib, Zimlovisertib, and Ropsacitinib in Hidradenitis Suppurativa". NEJM Evidence. 3 (3): EVIDoa2300155. doi:10.1056/EVIDoa2300155. PMID 38335032.
- ^ Wright SW, Farley KA, Han S, Knafels JD, Lee KL (April 2024). "In Retrospect: Root-Cause Analysis of Structure-Activity Relationships in IRAK4 Inhibitor Zimlovisertib (PF-06650833)". ACS Medicinal Chemistry Letters. 15 (4): 540–545. doi:10.1021/acsmedchemlett.4c00036. PMC 11017396. PMID 38628800.